Summary of minutes of EUCAST Steering Committee Meeting
Barcelona, Spain 13-14 May 2014

Attending
Dr Derek F.J. Brown  DB  Scientific Secretary  United Kingdom
Dr Rafael Cantón  RC  Chairperson  Spain
Prof Luc Dubreuil  LD  CA-SFM  France
Dr Christian Giske  CG  SRGA  Sweden
Prof Gunnar Kahlmeter  GK  Clinical Data Co-ordinator  Sweden
Prof Alasdair P. MacGowan  AM  BSAC  UK
Prof Luis Martinez-Martinez  LM  EUCAST General Committee  Spain
Prof Johan W. Mouton  JM  CRG  The Netherlands
Prof Sören Gatermann  SG  EUCAST General Committee  Germany
Dr Martin Steinbak  MS  NWGA  Norway
Dr Robert Skov  RS  EUCAST General Committee  Denmark

Visiting members:
Prof Ron Jones  RJ  EUCAST General Committee  USA
Prof John Turnidge  JT  EUCAST General Committee  Australia
Dr Radu Botgros  RB  EMA  UK
Dr Roland Grunow  QUANDHIP Project organizer  Robert-Koch-Institut, Berlin
Dr Tara Wahab  Public Health Agency Sweden

Chairman’s welcome RC welcomed RJ and JT as visiting members from the General Committee. Also RB from EMA. RS and LM have completed their terms on the Steering Committee and were thanked for their contributions.

Minutes of meeting of 11-12 February 2014 The minutes were accepted as a correct record.

Matters arising from minutes of 11-12 February 2014 (items not covered by agenda)
The French version of breakpoint tables will be reviewed as an example of how expert rules can be incorporated into breakpoint tables.

Collated MIC distributions for amoxicillin-clavulanic acid with a fixed 2 mg/L clavulanic acid have been separated on the website.

New agents Bedaquiline breakpoints and QC limits are to be added to the website.

EUCAST rationale documents A new template document will be released on the website. Several documents are currently being produced.

Subcommittees The Antifungal Susceptibility Testing Steering Committee structure has been revised. Two documents have been released for general consultation, MIC determination for moulds, and proposed itraconazole breakpoints for Candida spp.

Breakpoint issues
A consultation document on revised telavancin susceptibility testing and breakpoints will be released.

Revised doripenem breakpoints will need to be implemented by the company.

Breakpoints issues and methods for highly pathogenic microorganisms were discussed with QUANDHIP group representatives.

A proposal for ciprofloxacin breakpoints of S≤ 0.03, R >0.03 mg/L for Neisseria meningitidis will be released for consultation.

The guidance note on topical agents is now on the website.

Issues regarding possible sulbactam, cefoperazone-sulbactam and rifampicin breakpoints for Acinetobacter spp. were discussed.
The colistin working group have noted that the reference method for measuring MICs of polymyxins should not include polysorbate-80 in the medium. PK/PD studies are continuing, and polymyxin B susceptibility cannot be confidently predicted from colistin susceptibility.

The review of carbapenem breakpoints is continuing.

A document on organism-agent combinations lacking clinical data to support breakpoints has been posted on the website.

A review of the EUCAST expert rules is in progress.

A document summarising the current position and uncertainty on dissociated resistance to clindamycin will be distributed for comment with a request for any additional information.

Guidelines for manufacturers on data required for new antimycobacterial agents and susceptibility testing for mycobacteria are being discussed with the ESGMYC.

A note is being prepared on interpretation of the ampicillin-amoxicillin intermediate category for \textit{Streptococcus pneumoniae}.

The use of daptomycin to treat infections, including endocarditis, caused by enterococci is being assessed.

Review of tigecycline breakpoints and the development of breakpoints for nitroxoline, spiramycin and temocillin are being considered.

Correlation of ciprofloxacin and moxifloxacin MICs for \textit{Corynebacterium} spp. is to be added to the website.

Formation of a veterinary subcommittee on breakpoints is being considered.

**Organisms without EUCAST breakpoints** A guidance note on recommendations for testing \textit{Actinomyces} spp. is to be prepared.

**EUCAST methods**

Studies on QC ranges are underway for amoxicillin-clavulanate and ampicillin-sulbactam, \textit{E. coli} ATCC 25922 and pefloxacin, \textit{H. influenzae} ATCC 49766, \textit{E. faecalis} ATCC 29212 and fluoroquinolones, and several new agents.

Several projects are currently underway including comparison of “disks of particular importance” from several manufacturers, zone diameter breakpoints for UTI agents, zone diameter ECOFFs for \textit{Salmonella} spp. and \textit{Campylobacter} spp., \textit{Kingella kingae} disk diffusion methodology, zone diameter breakpoints for fosfomycin, breakpoints and disk diffusion tests for \textit{Aerococcus} spp., and breakpoints and disk diffusion tests for \textit{Salmonella} and azithromycin.

The EUCAST Method Development Laboratory in Växjö, Sweden will offer to do broth microdilution MIC determinations on a wide range of agents at a price to cover costs.

**Implementation of EUCAST breakpoints** Data from the UKNEQAS EQA scheme show that in February 2014 83.2% of participants used EUCAST breakpoints.

**EUCAST websites**

The frequently asked questions section has been updated.

An antimycobacterial agents section is to be added to the website.

Histogram presentation on the MIC and zone diameter website has been revised.

A note asking for expressions of interest in the international MIC distribution website project will be released.

**Publications and presentations** A CMI theme section on antimicrobial susceptibility testing is being prepared. A paper on uptake of EUCAST breakpoints is being assessed by Eurosurveillance.

**NACs.** The ESCMID Executive has appointed Belgium (Jan Verhagen) and Slovenia (Iztok Strumbelj) as
General Committee representatives on the Steering Committee for the next two years.

South Africa has joined the General Committee and formal applications from Morocco and Brazil were approved.

**EUCAST SOPs** SOP 8.0 on update and format of EUCAST documents will be released on the website.

**ESCMID**
At ECCMID 2014 the susceptibility testing workshop and “meet the experts” sessions were well attended and well received. Proposals for sessions for ECCMID 2015 were agreed.

Applications are being received for the Postgraduate Educational Course in Linz, 16-19 September 2014.

**EMA** There was a positive response to an EMA concept paper on PK/PD.

**New β-lactamase inhibitor combination** A preliminary presentation was made by the company.

**New lipoglycopeptide agent** A presentation was made by the company and breakpoint proposals discussed.

**Any other business** A WHO consultation document on rapid methods for antimicrobial susceptibility testing at point-of-care in lower- and middle-income countries was noted.

**Next meetings**
- 7-8 July 2014, Stockholm, Sweden.
- 15-16 September 2014, Linz, Austria
- 10-11 November 2014, Basel, Switzerland.
- 16-17 February 2015, Brussels, Belgium.
- 28-29 April 2015, Copenhagen, Denmark

Ratified summary of minutes of meeting 13-14 May 2014. Prepared by DB, RC and GK